ArticleInternational journal of cancer2026
Postnatal determinants of testicular germ cell tumor by histological subtypes: The EPSAM1 and EPSAM2 studies.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Postnatal determinants of testicular germ cell tumor by histological subtypes: The EPSAM1 and EPSAM2 studies.International journal of cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The EPSAM study is an ongoing case-control study evaluating the postnatal risk factors for testicular germ-cell tumor (TGCT). We aimed at updating the risk estimates for factors identified in previous EPSAM analyses and studying heterogeneities between seminomas and non-seminomas. TGCT cases (N = 358) and controls (N = 459) were recruited in two phases (EPSAM1, population-based, and EPSAM2, hospital based). We analyzed the associations with TGCT the following characteristics: (i) anthropometrics at different ages; (ii) baldness; (iii) sibship size; (iv) physical activity at age 13 years; and (v) hospitalizations up to age 18 years. Odds Ratios (ORs) for TGCTs and Relative Risk Ratios (RRRs) for seminomas and non-seminomas were estimated using unconditional and multinomial logistic regression models. We observed an increased risk of TGCT for height in childhood (OR: 1.83, 95% CI: 1.16-2.90, for taller vs. shorter than peers), pubertal height (OR: 1.40, 0.92-2.11, for taller vs. shorter than peers), adult height above the parental genetic target (OR: 1.47; 1.04-2.07), and any hospitalization in the first 18 years, in particular for diseases with an immune pathogenesis (OR 2.93, 1.33-6.44). Baldness, sibship size, and competitive sports at age 13 years were inversely associated with TGCT risk. Although all anthropometric characteristics were associated with seminomas and showed weaker or no associations with non-seminomas, there was little evidence of heterogeneity between the two, except for adult height compared to target height. The updated results of the EPSAM study support the role of postnatal environmental factors in TGCT etiology, with an overall lack of heterogeneity between seminomas and nonseminomas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.